• Je něco špatně v tomto záznamu ?

Development of a High-Throughput Screening Assay to Identify Inhibitors of the Major M17-Leucyl Aminopeptidase from Trypanosoma cruzi Using RapidFire Mass Spectrometry

M. Izquierdo, . Lin, S. O'Neill, M. Zoltner, L. Webster, A. Hope, DW. Gray, MC. Field, J. González-Bacerio

. 2020 ; 25 (9) : 1064-1071. [pub] 20200513

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026548

Grantová podpora
203134/Z/16/Z Wellcome Trust - United Kingdom
204697/Z/16/ Wellcome Trust - United Kingdom

Leucyl aminopeptidases (LAPs) are involved in multiple cellular functions, which, in the case of infectious diseases, includes participation in the pathogen-host cell interface and pathogenesis. Thus, LAPs are considered good candidate drug targets, and the major M17-LAP from Trypanosoma cruzi (LAPTc) in particular is a promising target for Chagas disease. To exploit LAPTc as a potential target, it is essential to develop potent and selective inhibitors. To achieve this, we report a high-throughput screening method for LAPTc. Two methods were developed and optimized: a Leu-7-amido-4-methylcoumarin-based fluorogenic assay and a RapidFire mass spectrometry (RapidFire MS)-based assay using the LSTVIVR peptide as substrate. Compared with a fluorescence assay, the major advantages of the RapidFire MS assay are a greater signal-to-noise ratio as well as decreased consumption of enzyme. RapidFire MS was validated with the broad-spectrum LAP inhibitors bestatin (IC50 = 0.35 μM) and arphamenine A (IC50 = 15.75 μM). We suggest that RapidFire MS is highly suitable for screening for specific LAPTc inhibitors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026548
003      
CZ-PrNML
005      
20211026132819.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2472555220923367 $2 doi
035    __
$a (PubMed)32400260
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Izquierdo, Maikel $u Centre for Protein Studies, Faculty of Biology, University of Havana, La Habana, Cuba
245    10
$a Development of a High-Throughput Screening Assay to Identify Inhibitors of the Major M17-Leucyl Aminopeptidase from Trypanosoma cruzi Using RapidFire Mass Spectrometry / $c M. Izquierdo, . Lin, S. O'Neill, M. Zoltner, L. Webster, A. Hope, DW. Gray, MC. Field, J. González-Bacerio
520    9_
$a Leucyl aminopeptidases (LAPs) are involved in multiple cellular functions, which, in the case of infectious diseases, includes participation in the pathogen-host cell interface and pathogenesis. Thus, LAPs are considered good candidate drug targets, and the major M17-LAP from Trypanosoma cruzi (LAPTc) in particular is a promising target for Chagas disease. To exploit LAPTc as a potential target, it is essential to develop potent and selective inhibitors. To achieve this, we report a high-throughput screening method for LAPTc. Two methods were developed and optimized: a Leu-7-amido-4-methylcoumarin-based fluorogenic assay and a RapidFire mass spectrometry (RapidFire MS)-based assay using the LSTVIVR peptide as substrate. Compared with a fluorescence assay, the major advantages of the RapidFire MS assay are a greater signal-to-noise ratio as well as decreased consumption of enzyme. RapidFire MS was validated with the broad-spectrum LAP inhibitors bestatin (IC50 = 0.35 μM) and arphamenine A (IC50 = 15.75 μM). We suggest that RapidFire MS is highly suitable for screening for specific LAPTc inhibitors.
650    _2
$a sekvence aminokyselin $x genetika $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a Chagasova nemoc $x diagnóza $x enzymologie $x parazitologie $7 D014355
650    12
$a rychlé screeningové testy $7 D057166
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a leucylaminopeptidasa $x genetika $x izolace a purifikace $7 D007931
650    _2
$a hmotnostní spektrometrie $7 D013058
650    _2
$a substrátová specifita $7 D013379
650    _2
$a Trypanosoma cruzi $x enzymologie $x izolace a purifikace $x patogenita $7 D014349
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lin, De $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK
700    1_
$a O'Neill, Sandra $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK
700    1_
$a Zoltner, Martin $u Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic
700    1_
$a Webster, Lauren $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK
700    1_
$a Hope, Anthony $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK
700    1_
$a Gray, David W $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK
700    1_
$a Field, Mark C $u Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK
700    1_
$a González-Bacerio, Jorge $u Centre for Protein Studies, Faculty of Biology, University of Havana, La Habana, Cuba $u Department of Biochemistry, Faculty of Biology, University of Havana, La Habana, Cuba
773    0_
$w MED00205671 $t SLAS discovery : advancing life sciences R & D $x 2472-5560 $g Roč. 25, č. 9 (2020), s. 1064-1071
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32400260 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132826 $b ABA008
999    __
$a ok $b bmc $g 1715314 $s 1147055
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 25 $c 9 $d 1064-1071 $e 20200513 $i 2472-5560 $m SLAS discovery $n SLAS Discov $x MED00205671
GRA    __
$a 203134/Z/16/Z $p Wellcome Trust $2 United Kingdom
GRA    __
$a 204697/Z/16/ $p Wellcome Trust $2 United Kingdom
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace